/TSBX
TSBX Stock - Turnstone Biologics Corp.
Healthcare|BiotechnologyNASDAQ
$0.35+0.00%
+$0.00 (+0.00%) • Aug 11
66
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.31
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.65
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+40.8%upside
Target: $0.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TSBX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.35 – $0.36
TARGET (TP)$0.50
STOP LOSS$0.33
RISK/REWARD1:5.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.37
52W High$2.26
52W Low$0.29
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | N/A | $19.31M | $73.30M | $101.29M |
| Gross Profit | $-1,835,000 | $16.51M | $71.10M | $99.28M |
| Gross Margin | N/A | 85.5% | 97.0% | 98.0% |
| Operating Income | $-72,494,000 | $-58,132,000 | $-31,626,000 | $32.99M |
| Net Income | $-70,837,000 | $-55,200,000 | $-30,834,000 | $33.27M |
| Net Margin | N/A | -285.9% | -42.1% | 32.8% |
| EPS | $-3.07 | $-2.73 | $-1.39 | $1.50 |
Company Overview
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
25%
Hold / Neutral
2
50%
Sell / Underperform
1
25%
Analyst Consensus🔴 Bearish
1 Bullish3 Neutral/Bearish
Price Targets
$13
Average Target
↑ 3505.6% Upside
Now
$0
Low
$13
Average
$20
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| February 5th 2025 | Piper Sandler | Downgrade | Neutral | $0.4← $3.75 |
| November 15th 2024 | BofA Securities | Downgrade | Underperform | - |
| October 14th 2024 | BofA Securities | Downgrade | Neutral | - |
| August 16th 2023 | SVB Securities | Initiation | Market Perform | - |
| August 15th 2023 | Piper Sandler | Initiation | Overweight | $20 |
| August 15th 2023 | BofA Securities | Initiation | Buy | $18 |
Earnings History & Surprises
TSBXBeat Rate
33%
Last 9 quarters
Avg Surprise
-35.2%
EPS vs Estimate
Beats / Misses
3/6
Last 12 quarters
Latest EPS
$-0.24
Q3 2025
EPS Surprise History
Q4 23
-49.3%
$-1.00vs$-0.67
Q1 24
+15.1%
$-0.73vs$-0.86
Q2 24
-9.0%
$-0.85vs$-0.78
Q3 24
-9.5%
$-0.92vs$-0.84
Q4 24
+14.9%
$-0.74vs$-0.87
Q1 25
+18.8%
$-0.56vs$-0.69
Q2 25
-96.2%
$-0.51vs$-0.26
Q3 25
-50.0%
$-0.24vs$-0.16
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 8, 2025 | $-0.16 | $-0.24 | -50.0% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.26 | $-0.51 | -96.2% | ✗ MISS |
Q1 2025 | Mar 28, 2025 | $-0.69 | $-0.56 | +18.8% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.87 | $-0.74 | +14.9% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-0.84 | $-0.92 | -9.5% | ✗ MISS |
Q2 2024 | May 13, 2024 | $-0.78 | $-0.85 | -9.0% | ✗ MISS |
Q1 2024 | Mar 21, 2024 | $-0.86 | $-0.73 | +15.1% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.67 | $-1.00 | -49.3% | ✗ MISS |
Q3 2023 | Sep 1, 2023 | $-3.00 | $-7.56 | -152.0% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | — | $0.00 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.62 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.73 | — | — |
Q2 2022 | Jun 30, 2022 | — | $0.52 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.57 | — | — |
Latest News
Loading news...
Frequently Asked Questions about TSBX
What is TSBX's current stock price?
Turnstone Biologics Corp. (TSBX) is currently trading at $0.35 per share. The stock has moved +0.00% today.
What is the analyst price target for TSBX?
The average analyst price target for TSBX is $0.50, based on 1 analyst.
What sector is Turnstone Biologics Corp. in?
Turnstone Biologics Corp. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is TSBX's market cap?
Turnstone Biologics Corp. has a market capitalization of $0.01 billion, making it a small-cap company.
Does TSBX pay dividends?
No, Turnstone Biologics Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAPGN
Apexigen, Inc.
$0.39
Mkt Cap: $0.0B
BIOR
Biora Therapeutics, Inc.
$0.22
Mkt Cap: $0.0B
CHRO
Channel Therapeutics Corporation
$1.35
Mkt Cap: $0.0B
CRVO
CervoMed Inc.
$7.60
Mkt Cap: $0.1B
CSCI
COSCIENS Biopharma Inc.
$2.11
Mkt Cap: $0.0B
IMVIF
IMV Inc.
$0.00
Mkt Cap: $0.0B
KA
Kineta, Inc.
$0.57
Mkt Cap: $0.0B
OMGA
Omega Therapeutics, Inc.
$0.14
Mkt Cap: $0.0B
TNFA
TNF Pharmaceuticals, Inc.
$5.20
Mkt Cap: $0.0B
TVRD
Tvardi Therapeutics, Inc.
$3.98
Mkt Cap: $0.0B
Explore stocks similar to TSBX for comparison